Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 14/20 | 0.86 |
| ▸ | BRD4 | O60885 | 9/20 | 0.86 |
| ▸ | BRDT | Q58F21 | 3/20 | 0.86 |
| ▸ | DCLK1 | O15075 | 9/20 | 0.81 |
| ▸ | MAPK7 | Q13164 | 11/20 | 0.78 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.72 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20094525 | 0.95 | MAPK7 (0.85) | LRRK2BRD4BRDTDCLK1MAPK7 | |
| SCHEMBL18313552 | 0.93 | MAPK7 (0.78) | LRRK2BRD4BRDTDCLK1MAPK7 | |
| SCHEMBL29389108 | 0.92 | LRRK2 (1.00) | LRRK2BRD4BRDTDCLK1MAPK7 | |
| SCHEMBL616761 | 0.92 | LRRK2 (1.00) | LRRK2BRD4BRDTDCLK1MAPK7 | |
| SCHEMBL29596956 | 0.92 | LRRK2 (1.00) | LRRK2BRD4BRDTDCLK1MAPK7 | |
| SCHEMBL616960 | 0.88 | LRRK2 (0.90) | LRRK2BRD4BRDTDCLK1MAPK7 | |
| SCHEMBL616339 | 0.87 | MAPK7 (1.00) | LRRK2BRD4BRDTDCLK1MAPK7 | |
| SCHEMBL20094179 | 0.86 | LRRK2 (0.69) | LRRK2BRD4BRDTDCLK1MAPK7 | |
| SCHEMBL31092826 | 0.86 | LRRK2 (0.69) | LRRK2BRD4BRDTDCLK1MAPK7 | |
| SCHEMBL16065732 | 0.86 | MAPK7 (0.89) | LRRK2BRD4BRDTDCLK1MAPK7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200338074-A1 | COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-10-29 | — | — | US | disclosed |
| US-10793571-B2 | Uses of diazepane derivatives | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-10-06 | — | — | US | disclosed |
| US-10702527-B2 | Combination therapy of transcription inhibitors and kinase inhibitors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-07-07 | — | — | US | disclosed |
| US-20190192532-A1 | COMBINATION THERAPY OF BROMODOMAIN INHIBITORS AND CHECKPOINT BLOCKADE | PETER MACCALLUM CANCER INSTITUTE (AU) | 2019-06-27 | — | — | US | disclosed |
| US-20190015411-A9 | COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-01-17 | — | — | US | disclosed |
| US-20180169097-A1 | COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-06-21 | — | — | US | disclosed |
| US-20180169097-A1 | COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-06-21 | — | — | US | disclosed |
| US-20170008895-A1 | USES OF DIAZEPANE DERIVATIVES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-01-12 | — | — | US | disclosed |
| US-20170008895-A1 | USES OF DIAZEPANE DERIVATIVES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10702527-B2 | Combination therapy of transcription inhibitors and kinase inhibitors | CHUK, BCOR, MYC | LRRK2 1732/4885BRD4 205/4885BRDT 85/4885 |
| US-20180169097-A1 | COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS | CHUK, BCOR, MYC | LRRK2 1732/4885BRD4 205/4885BRDT 85/4885 |
| US-20190015411-A9 | COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS | CHUK, BCOR, MYC | LRRK2 1732/4885BRD4 205/4885BRDT 85/4885 |
| US-20170008895-A1 | USES OF DIAZEPANE DERIVATIVES | BRDT, BRD4, BRD3 | LRRK2 1196/4885BRD4 2/4885BRDT 1/4885 |
| US-20190192532-A1 | COMBINATION THERAPY OF BROMODOMAIN INHIBITORS AND CHECKPOINT BLOCKADE | BRD4, BRD3, BRPF3 | LRRK2 1955/4885BRD4 1/4885BRDT 4/4885 |
| US-10793571-B2 | Uses of diazepane derivatives | BRDT, BRD4, BRD3 | LRRK2 1196/4885BRD4 2/4885BRDT 1/4885 |
| US-20200338074-A1 | COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS | CHUK, BCOR, MYC | LRRK2 1732/4885BRD4 205/4885BRDT 85/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.